Escalated radiation and prophylactic extended field nodal irradiation are beneficial for FIGO IIIB cervical cancer patients’ prognosis

Table 1 General patients’ information

Character	Group definition	Case	Ratio (%)
Age	≥65	24	10.7
Age	< 65	199	89.3
Pathology type	Squamous	206	92.3
Pathology type	Adenocarcinoma, Adeno/squamous Carcinoma	17	7.7
Tumor size	≤4 cm	48	21.5
Tumor size	> 4 cm	175	78.5
HGB prior treatment	< 110 g/L	69	30.9
	≥110 g/L	149	66.8
	N.A.	5	2.2
Pelvic LN metastasis	w/t	82	25.9
Pelvic LN metastasis	w/o	141	74.1
Para-aortic LN metastasis	w/t	31	13.9
Para-aortic LN metastasis	w/o	192	86.1
Concurrent chemotherapy	≥4 cycles	155	69.5
	< 4 cycles	45	20.10
	N.A	21	9.4
Radiotherapy	3D-CRT	48	21.5
Radiotherapy	IMRT	175	78.5
EQD2 (point A)	22-90Gy₁₀	30	13.4
	90–98 Gy₁₀	54	24.2
	≥98Gy₁₀	139	62.3
Therapy duration	≤63 days	175	78.5
Therapy duration	> 63 days	48	21.5
Prophylactic extended field irradiation	w/t	107	48.0
Prophylactic extended field irradiation	w/o	85	38.1

ISSN: 1748-717X